Skip to Content

Flamel Technologies Update

CEDEX, France, Nov. 26, 2008-Flamel Technologies has posted an updated presentation on its website.  The new presentation accounts for the initiation of an additional feasibility study to evaluate Medusa in conjunction with therapeutic vaccines.  The work is being conducted with a top-twenty pharmaceutical company with which the company is already engaged on two other projects. The presentation may be accessed at

Flamel Technologies, S.A. is a biopharmaceutical company principally engaged in the development of two unique polymer-based delivery technologies for medical applications. Flamel's Medusa® technology is designed to deliver controlled-release formulations of therapeutic proteins and peptidesMicropump® is a controlled release and taste-masking technology for the oral administration of small molecule drugs.

Charles Marlio, Director of Strategic Planning and Investor Relations
FRANCE: (011) 33-4-72-78-34-34
US:  (1) (202) 862-8400
Fax:  202-862-3933




Posted: November 2008